7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal Study [Yahoo! Finance]
Lexaria Bioscience Corp. (LEXX)
Company Research
Source: Yahoo! Finance
drug delivery platforms, informs that its wholly-owned and patented DehydraTECH-CBD formulation, when administered to rodents in an 8-week study (DIAB-A22-1), resulted in weight loss of 7% and a reduction of 19.9% (pLexaria has now signed contracts to begin animal study WEIGHT-A24-1; (the " Study "), which will be a large, multi-week animal study that will substantially progress its further DehydraTECH-GLP-1 and DehydraTECH-CBD weight loss investigations. Lexaria also recently published results in a human study, wherein a single 7 mg semaglutide dose from Rybelsus® processed with DehydraTECH and administered to humans, was absorbed at a significantly higher level than without DehydraTECH processing; and also managed blood glucose levels more effectively without any blood glucose spiking after eating. Together, these discoveries strongly support additional investigations, including: determining whether daily dosing of DehydraTECH-GLP-1 might result in sustained higher concentrati
Show less
Read more
Impact Snapshot
Event Time:
LEXX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEXX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEXX alerts
High impacting Lexaria Bioscience Corp. news events
Weekly update
A roundup of the hottest topics
LEXX
News
- Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 DrugsAccesswire
- Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance [Yahoo! Finance]Yahoo! Finance
- Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and IssuanceAccesswire
- Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study [Yahoo! Finance]Yahoo! Finance
- Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 StudyAccesswire
LEXX
Analyst Actions
- 3/5/24 - Maxim Group
LEXX
Sec Filings
- 5/2/24 - Form D
- 4/30/24 - Form 8-K
- 4/25/24 - Form SC
- LEXX's page on the SEC website